Finding the most stable AAVs for gene therapy is a critical step in development, and it's no secret that sample availability often gets in the way.
Having a tool that can do low-volume testing means better decisions can be made faster and earlier, leading to fewer wasted resources and development time on an unstable product.
Until now, traditional methods have failed in subvisible particle analysis due to their high volume requirements. But not any longer: Aura GT is the world's first ultra-low volume subvisible particle analysis platform, requiring only 5 µL of material.
This enables you to not only determine AAV stability and capsid integrity with ease, but also gain insight into AAV payload viability and product purity earlier on in the process.